Evercore ISI lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $4 from $16 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
- PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
- PMV Pharmaceuticals sees cash runway to end of 2Q27
- Pmv Pharmaceuticals, Inc. (PMVP) Q4 Earnings Cheat Sheet
- PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM